Please assess the completion status of the following clinical trial:

Trial Title: REDUCE - A Clinical Research Study To Reduce The Incidence Of Prostate Cancer In Men Who Are At Increased Risk

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria:~* Informed consent to participate in study.~* Have had a single negative prostate biopsy within 6 months prior to enrollment in study.~* Have a PSA (prostate specific antigen) between 2.5 and 10 if 50-60 years of age; or a PSA between 3.0 and 10 if over age 60.~* Ability and will to participate in study for 4 years.~Exclusion criteria:~* More than one previous negative prostate biopsy.~* History of prostate cancer.~* Previous prostate surgery.~* Inability to urinate requiring the need of a catheter during the previous 2 years.~* Any condition (other than benign prostatic hypertrophy) which may result in urinary symptoms or changes in urine flow rate.~* Cancer within previous 5 years (other than basal or squamous cell cancers of the skin).~* Any unstable serious medical condition.~* Use within the past 12 months of finasteride (Proscar or Propecia), dutasteride (Avodart), testosterone, or drugs that can block the action of male hormones.

- Gender: MALE
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Arm (Type: PLACEBO_COMPARATOR): Eligible subjects will complete a 4-week placebo run-in followed by randomization to matched placebo in a 1:1 ratio.
- dustasteride arm (Type: EXPERIMENTAL): Eligible subjects will complete a 4-week placebo run-in followed by randomization to 0.5mg dutasteride in a 1:1 ratio. Randomization will be stratified by center.

Based on this trial design, predict the completion outcome and termination type (if applicable).